| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5695473 | Gynecologic Oncology | 2017 | 6 Pages |
Abstract
Long-term MOGCT survivors treated with CBCT have small but significant reductions in age-adjusted hearing thresholds at 4, 6 and 8Â kHz versus Controls. Approximately one in four women experienced subjective hearing loss. To avoid overestimation of clinically relevant cisplatin-induced ototoxicity, absolute hearing thresholds should be age-adjusted and compared to an age-matched control group.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Jakob Skalleberg, Olesya Solheim, Sophie D. Fosså, Milada Cvancarova Småstuen, Terje Osnes, Per Ole M. Gundersen, Marie Bunne,